These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18088548)

  • 61. Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?
    Marchetti G; Franzetti F; Gori A
    J Antimicrob Chemother; 2005 Apr; 55(4):401-9. PubMed ID: 15731201
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART).
    Lin AL; Johnson DA; Sims CA; Stephan KT; Yeh CK
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep; 102(3):318-24. PubMed ID: 16920540
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy.
    Siddiqui U; Bini EJ; Chandarana K; Leong J; Ramsetty S; Schiliro D; Poles M
    J Clin Gastroenterol; 2007; 41(5):484-90. PubMed ID: 17450031
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Graves' disease during immune reconstitution in HIV-infected patients treated with HAART.
    Vos F; Pieters G; Keuter M; van der Ven A
    Scand J Infect Dis; 2006; 38(2):124-6. PubMed ID: 16449004
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibitor development and successful immune tolerance in an HIV-infected patient with haemophilia A and after immune reconstitution with HAART.
    Kruse-Jarres R; Hadi CM; Leissinger CA
    Haemophilia; 2007 Nov; 13(6):707-11. PubMed ID: 17973846
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical management considerations for dyslipidemia in HIV-infected individuals.
    Kirchner JT
    Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Subclinical hypothyroidism in HIV-infected subjects.
    Bongiovanni M; Adorni F; Casana M; Tordato F; Tincati C; Cicconi P; Bini T; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Nov; 58(5):1086-9. PubMed ID: 16950823
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia.
    Moreno A; Fortún J; Graus J; Rodriguez-Gandía MA; Quereda C; Pérez-Elías MJ; Nuño J; Wikman P; Moreno S; Bárcena R
    Liver Transpl; 2011 Mar; 17(3):331-3. PubMed ID: 21384516
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART).
    Steininger C; Puchhammer-Stöckl E; Popow-Kraupp T
    J Clin Virol; 2006 Sep; 37(1):1-9. PubMed ID: 16675299
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy.
    Palacios R; Santos J; González M; Ruiz J; Márquez M
    Int J STD AIDS; 2007 Mar; 18(3):184-7. PubMed ID: 17362552
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Deficient in vitro anti-mycobacterial immunity despite successful long-term highly active antiretroviral therapy in HIV-infected patients with past history of tuberculosis infection or disease.
    Mendonça M; Tanji MM; Silva LC; Silveira GG; Oliveira SC; Duarte AJ; Benard G
    Clin Immunol; 2007 Oct; 125(1):60-6. PubMed ID: 17631053
    [TBL] [Abstract][Full Text] [Related]  

  • 73. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
    Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Puthanakit T; Aurpibul L; Yoksan S; Sirisanthana T; Sirisanthana V
    Vaccine; 2007 Nov; 25(49):8257-61. PubMed ID: 17964009
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expert commentary: the safety of fibrates in lipid-lowering therapy.
    Brown WV
    Am J Cardiol; 2007 Mar; 99(6A):19C-21C. PubMed ID: 17368273
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Neurophysiological abnormalities in HIV-infected long term survivors.
    Kellinghaus C; Wibbeke B; Evers S; Reichelt D; Pollmann H; Husstedt IW
    Eur J Med Res; 2006 Jun; 11(6):245-9. PubMed ID: 16820337
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with CD4 cell recovery after HAART initiation.
    Ingiliz P; Appenrodt B; Gruenhage F; Vogel M; Tschampa H; Tasci S; Rockstroh JK
    HIV Med; 2006 Sep; 7(6):411-4. PubMed ID: 16903987
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.
    Calza L; Manfredi R; Chiodo F
    AIDS; 2003 Apr; 17(6):851-9. PubMed ID: 12660532
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High-risk dysmetabolism disorders associated with HAART-treated HIV disease, and reimbursement of lipid-lowering drugs, in a clinical and a socio-economic perspective.
    Manfredi R
    AIDS Rev; 2005; 7(3):155-60. PubMed ID: 16302463
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids.
    Metroka CE; Truong P; Gotto AM
    AIDS Read; 2007 Jul; 17(7):362-4, 367-73. PubMed ID: 17672015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.